Case Report: Systemic Treatment and Serial Genomic Sequencing of Metastatic Prostate Adenocarcinoma Progressing to Small Cell Carcinoma

XiaoJun Lu†, Wenwen Gao‡, Yu Zhang‡, Tao Wang, Hongliang Gao, Qing Chen, Xiaolei Shi, Bijun Lian, Wenhui Zhang*, Xu Gao* and Jing Li*

1 Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China, 2 Department of Oncology, Shidong Hospital, Affiliated to University of Shanghai for Science and Technology, Shanghai, China, 3 Department of Bioinformatics, Center for Translational Medicine, Second Military Medical University, Shanghai, China, 4 Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 5 Department of Urology, The 903th PLA Hospital, Hangzhou, China

Small cell carcinoma (SCC)/neuroendocrine prostate cancer (NEPC) is a rare and highly aggressive subtype of prostate cancer associated with an AR(androgen receptor)-null phenotype and visceral metastases. This study presents a 44-year-old man originally diagnosed with metastatic hormone-sensitive prostatic adenocarcinoma. After 6-month androgen deprivation therapy (ADT) combined with docetaxel, the patient developed paraplegia. Laminectomy was performed, and a thoracic vertebral biopsy revealed neuroendocrine differentiation and mixed adenocarcinoma. The patient developed liver metastases and experienced stable disease for 4 months following etoposide combined with cisplatin and pembrolizumab. Seminal vesicle biopsy after chemotherapy revealed small-cell cancer. The prostate biopsy specimen also indicated pure SCC. We witnessed the dynamic evolution from pure adenocarcinoma to fully differentiated SCC, leading to obstruction and death. In addition, whole-exome sequencing was performed on both biopsy specimens of the thoracic vertebra at the beginning of castration resistance and that of seminal vesicle after multiple lines of treatment failure. Utilizing phylogenetic reconstruction, we observed that both samples shared a common ancestor clone harboring aberrations in the TP53, RB1, and NF2 genes. We also discovered that driver events in the private subclones of both samples, such as alterations in CDC27 and RUNX1, might have played a significant role in tumor progression or even neuroendocrine differentiation. Tumor biopsy and IHC assessment must be repeated at different stages of progression, because of intrapatient spatial and temporal heterogeneity of adenocarcinoma versus SCC/NEPC. Although, typical treatments including ADT, docetaxel, etoposide, cisplatin, and pembrolizumab provided temporary response, the patient still had a poor prognosis.

Keywords: neuroendocrine differentiation, small cell carcinoma, whole-exome sequencing, neuroendocrine prostate cancer, clonal evolution
INTRODUCTION

The androgen receptor (AR) regulates of growth and proliferation of prostate cancer (1). Androgen-deprivation or highly potent AR-targeted therapies, such as enzalutamide, remain the mainstay for the systematic treatment of metastatic hormone-sensitive prostate cancer (mHSPC). However, majority of the mHSPC cases eventually develop to metastatic castration-resistant prostate cancer (mCRPC) after long-term androgen deprivation therapy (ADT). An important mechanism in treatment-resistant prostate cancer development might be associated with neuroendocrine differentiation. Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer, characterized by pure or mixed neuroendocrine differentiation. Histologically, small cell neuroendocrine carcinoma is among the highest-grade and poorly differentiated neuroendocrine tumors. Small cell carcinoma constitutes 0.5–2% of prostate cancer cases, whereas 10–20% of CRPC cases; however, the current prevalence of SCC/NEPC after intense therapeutic pressures designed to inhibit AR signaling might be higher (2). Using molecular classifiers some studies have supported the clonal evolution trajectory of NEPC from adenocarcinoma (3).

Here, we present a case that shows the transformation process from adenocarcinoma to neuroendocrine cells and small cell prostate cancer at a very late stage. We found the coexistence of heterogeneous subtypes in the whole body during treatment, which elicited different reactions to different treatments. Furthermore, we performed serial molecular profiling and explored the clonal evolution pattern of NEPC to small cell carcinoma in this patient after treatment to help understand the potential mechanism of this evolutionary path.

CASE DESCRIPTION

In June 2018, a 44-year-old man was originally diagnosed with prostate cancer (PCa) confirmed using prostate biopsy, which indicated a Gleason score of 4 + 5 = 9 prostate adenocarcinomas involving all 15 cores (Figure 1A). From June 2018 to December 2020, the patient presented with three stages of prostate cancer, according to treatment, mHSPC, mCRPC, and small cell. Immunohistochemical (IHC) assessment demonstrated tumors to be positive for prostate-specific membrane antigen (PSMA), P504s, and P501s (Table 1). Prostate-specific antigen (PSA) levels were initially elevated at 147.7 ng/mL. Whole-body magnetic resonance imaging (WB-MRI) indicated metastases involving the prostate capsule, bilateral seminal vesicles, pelvic lymph nodes, and extensive osteosclerotic lesions (Figure 1C). Hence, the patient was diagnosed with cT3bN1M1b stage cancer. Because of the high tumor burden, we began treatment for mHSPC with ADT plus docetaxel at 75 mg/m² for six cycles. Following this, the PSA levels showed a rapid and significant improvement, dropping to 0.004 ng/mL in December 2018. Both WB-MRI and a bone scan showed no obvious active lesions in the prostate, pelvic lymph nodes, and bones (Supplementary Figure 1).

Although ADT plus docetaxel therapy achieved periodic results in the treatment of mHSPC, his levels of PSA increased continuously with ADT therapy alone over 5 months after stopping chemotherapy, reaching 0.132 ng/mL in May 2019. Meanwhile, PSMA positron emission tomography (PET)/computed tomography (CT) revealed the presence of metabolically active lesions in multiple bones, but not in the prostate (Figure 1C). Therefore, we assumed that the mHSPC had progressed to mCRPC. In July 2019, we treated the patient with ADT and abiraterone for over 3 months. However, his levels of PSA continued to increase, and a severe complication of paraplegia occurred in October 2019. The patient underwent laminectomy in November 2019, which led to improved motor capacity. The posttreatment thoracic vertebral biopsy specimen revealed metastatic prostate adenocarcinoma with neuroendocrine differentiation (Figure 1B). IHC assessment demonstrated tumors to be positive for PSMA, P504s, NKX3.1, synaptophysin (Syn), CD56, chromogranin A (CgA), AR (+, 80%), and Ki67 (+, 40%) (Table 1). A fresh portion of the vertebral specimen was sent for tumor sequencing.

One month later, the patient had elevated levels of transaminases. Magnetic resonance imaging (MRI) revealed new lesions in the liver (Figure 2A). Neuron-specific enolase (NSE) levels were elevated at 36.23 ng/mL (Figure 1A). Based on the pathology and clinical features, we initiated etoposide at 80 mg/m² combined with cisplatin at 25 mg/m², and continued ADT therapy plus pembrolizumab specific for NEPC. After several cycles, an MRI showed that the liver lesions had almost disappeared (Figure 2B).

Following four cycles of etoposide combined with cisplatin plus pembrolizumab, the patient experienced severe general bone pain and blurred vision. His levels of PSA were transiently decreased, but increased again to 1.826 ng/mL in the last four cycles, whereas his levels of NSE decreased to 10.53 ng/mL. A new MRI revealed metastases involving the clivus and adjacent right sphenoid bone (Figure 2C). Hence, we hypothesized the coexistence of mixed adenocarcinoma and neuroendocrine components. In particular, we considered that the NSE signal showed the efficiency, while the levels of PSA represented the growth of adenocarcinoma components. Therefore, we attempted treatment with docetaxel at 75 mg/m², cisplatin at 25 mg/m², and continued ADT therapy plus pembrolizumab. Notably, the patient recovered his vision and experienced pain relief. After four cycles, his symptoms improved significantly. However, PSMA-PET/CT revealed metabolically active lesions on the left seminal vesicle, liver, and multiple bones, indicating cancer progression (Figure 1C). In addition, a seminal vesicle biopsy in July 2020 revealed small cell carcinoma. IHC assessment demonstrated tumors to be positive for CAM5.2, Syn, CD56, CgA, AR (+, 30%), and Ki-67 (+, 100%), but negative for NKX3.1 and P501s (Table 1). A fresh portion of this seminal vesicle specimen was sent for tumor sequencing. Three months later, the patient underwent palliative transurethral resection of prostate (TURP) for dysuria. The prostate biopsy specimen indicated small cell carcinoma. IHC assessment demonstrated tumors to be positive for P504s,
CAM5.2, Syn, CD56, CgA, ERG, PTEN, and Ki-67(+, 100%), but negative for NKX3.1 and PSMA.

MOLECULAR TUMOR BOARD
Pathology and Molecular Evolution From Adenocarcinoma to NEPC to SCC

Neuroendocrine differentiation in adenocarcinoma should be detected in a timely manner. Both the elevation of serum NSE levels and the presence of visceral metastases indicate the development of neuroendocrine differentiation in prostate cancer. Despite their high sensitivity, the CgA and NSE serum neuroendocrine markers lack specificity for SCC/NEPC (2, 4, 5). Pathological diagnosis is the most reliable diagnosis, and the acquisition of reliable biopsy specimens usually depends on good compliance of the patient and the puncture technique of the doctor (6). We obtained four pre- and posttreatment biopsy specimens, which revealed the histological progression of tumors (Table 1) (Supplementary Figure 2). PSMA, P504s, and NKX3.1 were expressed in nearly all prostatic adenocarcinomas. Only these markers were expressed at initial diagnosis, indicating the adenocarcinoma origin of the tumor. The CgA, Syn, and CD56
markers are expressed in nearly all prostate cancers with neuroendocrine differentiation (7). Following its progression to mCRPC, IHC assessment of the thoracic vertebral biopsy specimen revealed positive signals for PSMA, P504s, NKX3.1, Syn, CD56, and CgA, which indicated adenocarcinoma admixed with NEPC after intense therapeutic pressures of ADT therapy. Likewise, IHC assessment of the seminal vesicle biopsy specimen showed positive signals for CAM5.2, Syn, CD56, and CgA, but negative for NKX3.1 and P501s, indicating the predominance of SCC/NEPC in the patient during this period. Under the pressure of treatment, NEPC transformed into a poorly differentiated small cell phenotype, losing the expression of adenocarcinoma origin-specific markers, such as PSMA and NKX3.1.

**Functional and Clinical Significance of Specific Mutations in This Case**

As the special genetic pattern of NEPC reflects its cellular origin, the genetic alterations in two samples collected at different stages were investigated using whole-exome sequencing. The first was a mixed adenocarcinoma and neuroendocrine cancer sample (M-sample) at CRPC, whereas the second was a pure SCC/NEPC (S-sample) at the last stage. We described the mutational landscape and applied phylogenetic reconstruction to analyze the dynamic clonal progression. We estimated and clustered the genetic alterations in two samples collected at different stages using whole-exome sequencing. An AR amplification was detected in the M-sample but not in the second pure SCC/NEPC sample, indicating the downregulation of AR in NEPC (12). Although Beltran et al. observed that the RUNX1 copy number deletion was meaningful in NEPC, a RUNX1 amplification could also occur, further supporting the key role of RUNX1 in neuroendocrine-differentiated tumors (13). Consequently, the two samples obtained individual subclones after MRCA in the clonal evolutionary tree (Figures 3C, D). Some driving events in these subclones might have played a key role in tumor progression or even in promoting neuroendocrine differentiation.

**DISCUSSION**

**Potential Strategies to Target the Pathway and Implications for Clinical Practice**

Precision oncology is based on tumor biopsies and sequencing to identify therapeutic targets. Here, two posttreatment biopsy specimens with histologic progression were analyzed using whole-exome sequencing. An AR amplification was detected in the first mixed tumor sample but not in the second pure SCC/NEPC sample, indicating the downregulation of AR in NEPC compared with that in adenocarcinoma (5, 13). In addition, the inactivation of RB1 and TP53 tumor suppressor genes is frequently associated with small cell cancer (14, 15), and is a key mechanism of resistance to antiandrogen therapy and lineage plasticity (16, 17). Identical mutations in the DNA-
binding domains of TP53, RB1, and MYC have also been observed in both NGS profiles, indicating the possible derivation of NEPC from adenocarcinoma (18–20). We attempted to identify therapeutic targets, such as DNA damage repair (DDR) pathway genes (BRCA1, BRCA2, ATM, and CDK12), which could be paired with poly ADP-ribose polymerase (PARP) inhibitors (6, 21). However, we did not detect any alterations in DDR pathway genes in the NGS profiling. Similarly, other studies have also shown the rare occurrence of alterations in DDR pathway genes in SCC/NEPC (2). We observed alterations in PIK3CA and NF2, which could be associated with the phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway. However, the curative effect of mTOR inhibitors in prostate cancer remains uncertain (22, 23). Considering the uncertain curative effect and the poor physical condition of the patient, we elected the regimen recommended by the guidelines (6, 24).

Prostate cancer with neuroendocrine differentiation shows remarkable clinical heterogeneity, as revealed by the constantly changing clinical symptoms, such as bone pain, liver metastases, and meningeal metastases. We deduced that adenocarcinoma and SCC/NEPC alternately dominated the shift in the process of disease. We elected ADT combined with docetaxel as the initial treatment, but changed to etoposide combined with cisplatin and pembrolizumab after the detection of neuroendocrine differentiation. In this case, the key advantage of the approach used is the timely correction of treatment strategy according to the pathological type and the construction of tumor subclone structures using sequential sampling. In addition, we advanced chemotherapy at the initial diagnosis based on the NCCN
guidelines (6), and timely chose the regimen with etoposide and platinum (EP) + PD1 when the tumor was revealed to be neuroendocrine differentiation and mixed adenocarcinoma. Despite accomplishing a temporary response, regrettably, we could not find a regimen that could ideally control both adenocarcinoma and SCC/NEPC to improve the prognosis. We have also supplemented our report with the research on the origin of SCC/NEPC from the perspective of clonal evolution. Previous studies have reported the transdifferentiation phenomenon of NEPC and its molecular changes, that is, prostate adenocarcinoma cells could transform into a neuroendocrine phenotype (25, 26). We described here the clonal evolution from mixed adenocarcinoma and neuroendocrine cancer to pure SCC/NEPC. Meanwhile, some

FIGURE 3 | The altered landscape and phylogenetic reconstruction of the two samples. (A) The second panel shows the cancer cell fraction estimated by using PyClone and calculated using the read depth of mutations, copy numbers, and purity of tumors. Other panels are showing the frequency of mutations in three types of prostate cancer using public data from the cBioPortal (1400 primary tumors, 54 NEPC samples, and 880 mCRPC samples). Important functional cancer genes are marked in red. (B) Overview of copy number alterations and cancer genes encompassed in segments are shown in red. (C, D) Fishplot indicating the dynamic clonal progression of the tumor, and clonal evolution tree showing the phylogenetic relationship between the two samples.
molecular alterations have also been provided, which could hopefully be used to monitor the progress of SCC/NEPC in the future.

Notably, this case study has some limitations. While longitudinal sampling combined with bulk sequencing could distinguish tumor subclones and monitor tumor progression, for the special tumor type observed in this case—with higher heterogeneity and more complex cellular components—single-cell sequencing may be a better and more accurate solution (27). Alternatively, in a previous report, transcription factors have been utilized for the molecular subtyping of small cell lung cancer; however, this has not been applied in clinical practice (28). Accordingly, further research is required to explore the value of transcription factor typing to guide clinical treatment.

**Patient Update**

Despite a periodic clinical response, the patient died from respiratory failure, severe anemia, infection, and brain edema in December 2020. The last MRI showed metastases of the meninges, clivus, skull, and sphenoid bone (Figure 2D).

**Key Points**

If the IHC assessment of the initial puncture biopsy tissue detects potential neuroendocrine differentiation, doctors should offer patients more frequent imaging examination and analyses of serum markers.

Tumor biopsy and IHC assessment must be repeated at different stages of the disease to judge the progress of neuroendocrine differentiation and adjust the treatment regimen.

Tumor sequencing remains necessary even though changes might not be necessarily detected, as it could help clinicians better understand the genomic changes during neuroendocrine differentiation.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

**REFERENCES**

1. C. Global Burden of Disease Cancer, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The Global Burden of Cancer 2013. *JAMA Oncol* (2015) 1:505–27. doi: 10.1001/jamaoncol.2015.0735
2. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-Institutional Prospective Study. *J Clin Oncol* (2018) 36:2492–503. doi: 10.1200/JCO.2017.77.6880
3. Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, et al. Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer. *J Clin Oncol* (2012) 30:e386–389. doi: 10.1200/JCO.2011.41.5166
4. Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, et al. The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. *Clin Cancer Res* (2016) 22:1510–9. doi: 10.1158/1078-0432.CCR-15-0137
5. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, et al. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. *Mod Cancer Res* (2019) 17:1235–40. doi: 10.1158/1541-7786.MCR-18-1101
6. Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. *J Natl Compr Canc Netw* (2021) 19:134–43. doi: 10.6004/jnccn.2021.0008
7. Shariﬁ AH, Ather MH. Neuroendocrine Differentiation in Prostate Cancer. *Urology* (2006) 68:2–8. doi: 10.1016/j.urology.2006.02.002
8. Roth A, Khattra J, Yap D, Wan A, Laks E, Biele J, et al. PyClone: Statistical Inference of Clonal Population Structure in Cancer. *Nat Methods* (2014) 11:396–8. doi: 10.1038/nmeth.2883
9. Ashkar T, Ali SM, Welsh A, Dhir R, Gollin SM, Parkh RA. A Prolonged Response to Platinum-Based Therapy in a Patient With Metastatic Urothelial Carcinoma Harboring a Single Rearranged and Truncated NF2 Gene. *Genes Chromosomes Cancer* (2018) 57:430–3. doi: 10.1002/gcc.22537

**AUTHOR CONTRIBUTIONS**

Conception/design: JL and WZ. Provision of study material or patients: TW and HG. Collection and/or assembly of data: YZ and XS. Data analysis and interpretation: WZ and QC. Manuscript writing: XL and WG. Manuscript revision: XG. Final approval of manuscript: BL and JL. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by the Shanghai Rising-Star Program (20QA1411800) and National Natural Science Foundation of China (82022055).

**ACKNOWLEDGMENTS**

We also would like to thank Shanghai OrigiMed Clinical Laboratory Co., Ltd. for Whole-exome sequencing service and Editage (https://www.editage.com/) for English language editing.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.732071/full#supplementary-material

**Supplementary Figure 1** | Figure WB-MRI shows there were no obvious active lesions in prostate, pelvis lymph nodes, and bones all over the body in January 2019 after six chemotherapy cycles of docetaxel along with ADT therapy.

**Supplementary Figure 2** | Positive IHC assessment of puncture tissue of prostate, thoracic vertebra biopsy specimen, seminal vesicle tissue, and prostate after TURP.

**Supplementary Table 1** | Summary whole exome sequencing findings from the thoracic vertebra biopsy specimen and the seminal vesicle specimen. Variants were identified including single nucleotide variants(SNV), small insertion-deletions, and copy number alterations. The cancer cell fractions(CCF) and clusters of each mutations are also indicated.
10. Li J, Xu C, Lee HJ, Ren S, Zi X, Zhang Z, et al. A Genomic and Epigenomic Atlas of Prostate Cancer in Asian Populations. *Nature* (2020) 580:93–9. doi: 10.1038/s41586-020-2135-x

11. Kazemi-Sefat GE, Keramatipour M, Talebi S, Kavousi K, Sajed R, Kazemi-Sefat NA, et al. The Importance of CDC27 in Cancer: Molecular Pathology and Clinical Aspects. *Cancer Cell* (2021) 21:e160. doi: 10.1016/j.ccell.2021.01.001

12. Delcèche E, Nimmo R. Runx Transcription Factors at the Interface of Stem Cells and Cancer. *Biochem J* (2017) 474:1755–68. doi: 10.1042/BC20160632

13. Beltran H, Prandi D, Mosquesa JM, Benelli M, Puca L, Cyrta J, et al. Divergent Clonal Evolution of Castration-Resistant Neuroendocrine Prostate Cancer. *Nat Med* (2016) 22:298–305. doi: 10.1038/nm.4045

14. Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, et al. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. *Clin Cancer Res* (2016) 22:1520–30. doi: 10.1158/1078-0432.CCR-15-1259

15. Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, et al. Substantial Interindividual and Limited Intraindividual Genomic Diversity Among Tumors From Men With Metastatic Prostate Cancer. *Nat Med* (2016) 22:369–78. doi: 10.1038/nm.4053

16. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance. *Science* (2017) 355:78–83. doi: 10.1126/science.aah4199

17. Park JW, Lee JK, Sheu KM, Wang L, Balansingh N, Nguyen K, et al. Reprogramming Normal Human Epithelial Tissues to a Common, Lethal Neuroendocrine Cancer Lineage. *Science* (2018) 362:91–5. doi: 10.1126/science.aat7549

18. Nadal R, Schweizer M, Kryvenko ON, Epstein JJ, Eisenberger MA. Small Cell Carcinoma of the Prostate. *Nat Rev Urol* (2014) 11:213–9. doi: 10.1038/nrurrol.2014.21

19. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. *Clin Cancer Res* (2013) 19:3621–30. doi: 10.1158/1078-0432.CCR-12-3791

20. Beltran H, Rickman DS, Park K, Chae SS, Stoner A, MacDonald TY, et al. Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. *Cancer Discovery* (2011) 1:487–95. doi: 10.1158/2159-8290.CD-11-0130

21. Loeb S, Giri VN. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. *Eur Urol Oncol* (2021) 4:1–9. doi: 10.1016/j.euo.2020.11.011

22. de Bono JS, De Giorgi U, Rodrigues DN, Massard C, Bracarda S, Font A, et al. Randomized Phase II Study Evaluating Akt Blockade With Ipatasertib, in Combination With Abiraterone, in Patients With Metastatic Prostate Cancer With and Without PTEN Loss. *Clin Cancer Res* (2019) 25:928–36. doi: 10.1158/1078-0432.CCR-18-0981

23. Statz CM, Patterson SE, Mockus SM. mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review. *Target Oncol* (2017) 12:47–59. doi: 10.1007/s11523-016-0453-6

24. Wu Y, Gao Y, Dou X, Yue J. Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review. *Onco Targets Ther* (2020) 13:8049–54. doi: 10.2147/OTT.S264347

25. Kadakia KC, Tomlins SA, Sanghvi SK, Cani AK, Omata K, Hovelson DH, et al. Comprehensive Serial Molecular Profiling of an “N of 1” Exceptional non-Responder With Metastatic Prostate Cancer Progressing to Small Cell Carcinoma on Treatment. *J Hematol Oncol* (2015) 8:189. doi: 10.1186/s13045-015-0204-7

26. Terry S, Beltran H. The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression. *Front Oncol* (2014) 4:60. doi: 10.3389/fonc.2014.00060

27. Dong B, Miao J, Wang Y, Luo W, Ji Z, Lai H, et al. Single-Cell Analysis Supports a Luminal-Neuroendocrine Transdifferentiation in Human Prostate Cancer. *Commun Biol* (2020) 3:778. doi: 10.1038/s42003-020-01476-1

28. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive Genomic Profiles of Small Cell Lung Cancer. *Nature* (2015) 524:47–53. doi: 10.1038/nature14664

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2021 Lu, Gao, Zhang, Wang, Gao, Chen, Shi, Lian, Zhang, Gao and Li.**